New KDIGO Publications on IgAN, B-Cell Therapies, and CKM | | |
Three KDIGO publications in the September issue of Kidney International address distinct areas of kidney care, including new treatment options in IgA nephropathy (IgAN), B cell–targeted therapies in immune-mediated kidney diseases, and the role of the kidney in cardiovascular-kidney-metabolic (CKM) health.
Complement inhibitors and B cell–modifying agents for IgA nephropathy—a KDIGO commentary addresses treatments that emerged after the KDIGO 2025 IgAN/IgAV Guideline went to press. Three additional therapies subsequently received accelerated approval from the US Food and Drug Administration. Rather than undertaking another guideline update while evidence continues to accumulate, the guideline Work Group developed the commentary to consider how the new therapies may fit into the overall IgAN treatment strategy. The commentary discusses the endothelin A receptor antagonist atrasentan, the complement inhibitor iptacopan, and the APRIL-targeting therapy sibeprenlimab, while noting that available therapies cannot currently be ranked in the absence of head-to-head trials.
Targeting B cells in immune-mediated kidney diseases: conclusions from a KDIGO Controversies Conference examines established and emerging approaches across IgAN, membranous nephropathy, podocytopathies, lupus nephritis, and ANCA-associated glomerulonephritis. Drawing on the KDIGO conference held in Panama City, Panama in June 2025, the report highlights important differences in the effectiveness and safety of B cell–targeted therapies among diseases and identifies priorities for future research, including better biomarkers, treatment protocols, optimal treatment duration, and long-term safety.
The kidney in the middle: KDIGO guidelines address multiple key components of cardiovascular-kidney-metabolic syndrome considers CKM syndrome through the lens of KDIGO guidance. The paper highlights how KDIGO guidelines and reports on CKD, diabetes, blood pressure, lipids, obesity, CKD prevention, and heart failure in CKD address key components of CKM health. Common priorities include earlier detection and intervention, comprehensive and personalized management of kidney and cardiovascular risk, and multidisciplinary care.
Read all three publications in the September issue of Kidney International.
| | KDIGO ECP Publishes Article on Kidney Paired Exchange in Germany | | |
KDIGO Early Career Professional (ECP) Program mentee Louise Benning, MD (Germany), has published a new article in Kidney International Reports examining Germany’s move toward kidney paired exchange (KPE) and nondirected living kidney donation. The article, Germany’s Move Toward Kidney Paired Exchange and Nondirected Donation: Governance Lessons From Abroad, was developed as part of Benning’s ECP project in collaboration with her KDIGO ECP mentor, Michelle Josephson, MD (United States), Co-Chair of the forthcoming KDIGO Care of the Kidney Transplant Recipient Guideline Update and a member of the KDIGO Executive Committee. Wan-Zi Lu (United States) and Klemens Budde, MD (Germany), are co-authors.
The article comes as Germany moves toward establishing a legal framework for KPE and nondirected anonymous living kidney donation. Drawing on international experience, the authors highlight key considerations for implementation, including registry governance and accountability, transparent rulemaking, donor safeguards, equity and access, and public trust.
The authors conclude that successful implementation will depend not only on increasing opportunities for transplantation, but on building a nationally coordinated system with clear accountability, transparent rules, and strong independent protections for living donors.
Read the article in Kidney International Reports.
| | KDIGO is delighted to take part in the Brazilian Congress of Nephrology (CBN), September 16–19, 2026, in Belo Horizonte, Brazil. KDIGO leaders and experts will join colleagues from Brazil and around the world for sessions addressing key priorities in kidney health, including cardio-kidney-metabolic health, acute kidney injury, IgA nephropathy, women and kidney health, and guideline implementation. Learn more. | | |
KDIGO at The Transplantation Society (TTS) 2026 Congress
Tuesday, September 22, 2026, 5:00 - 6:00 PM AEST
International Convention Centre, Room C3.3 (Level 3), Sydney, Australia
Live Session
Don't miss the KDIGO session at the TTS 2026 Congress, “State-of-the-Art Care for Kidney Transplant Recipients: Implications for the Forthcoming KDIGO Guideline Update.”
Since the publication of the first KDIGO guideline on the care of kidney transplant recipients in 2009, significant advances have reshaped the field. Forthcoming KDIGO Care of the Kidney Transplant Recipient Guideline Update Co-Chairs Michelle Josephson, MD (United States), and Germaine Wong, MD (Australia), along with John Gill, MD (Canada), will explore what has changed in kidney transplantation, evolving therapeutic needs, and emerging research with implications for the guideline update, clinicians, and transplant recipients. Learn more.
| |
KDIGO at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
Thursday, October 1, 12:30 - 14:00 CEST
Allianz MICO - Milan Convention Centre, Berlin Hall, Milan, Italy
Live Meeting Session
At EASD 2026, KDIGO will present “Matters Arising for Kidney and Diabetes: What's New from KDIGO,” highlighting current and forthcoming work addressing the interconnected challenges of diabetes, kidney disease, and cardiovascular health. Christoph Wanner, MD (Germany), Katherine Tuttle, MD (United States), Peter Rossing, MD (Denmark), and Paola Fioretto, MD (Italy) will discuss KDIGO’s work in cardiovascular-kidney-metabolic health, the forthcoming update to the KDIGO Diabetes Guideline, and the new KDIGO Prevention of CKD Consensus Report. Learn more.
| | |
Latest IgAN Developments: KDIGO Updates from GlomCon 2026
Expert Video
In this video recorded at GlomCon 2026 in Maui, Hawaii, nephrologist and clinical trialist Vlado Perkovic, MD (Australia) discusses the latest developments in IgA nephropathy (IgAN) and the rapidly evolving treatment landscape.
Professor Perkovic highlights new 2-year kidney function and safety data from the phase 3 VISIONARY trial of sibeprenlimab, the emerging role of APRIL/BAFF-targeted therapies, and other recent and upcoming clinical trial findings that could shape the future of IgAN care. Watch now.
| | |
KDIGO FSGS Podcast Series
KDIGO Conversations in Nephrology Podcast Series
The latest KDIGO Conversations in Nephrology podcast series takes a closer look at the evolving science and management of focal segmental glomerulosclerosis (FSGS). Hosted by Kirk Campbell, MD (United States), the three-part series features Alessia Fornoni, MD (United States), Laura Mariani, MD (United States), and Jai Radhakrishnan, MD (United States).
Across the series, experts explore the evolving understanding of FSGS and podocyte injury, the role of proteinuria in treatment and clinical trials, and advances in FSGS management, including emerging targeted therapies and precision medicine. Listen on your favorite podcast platform.
| | |
The Chronic Kidney Disease Checkpoint: Keeping Current in Anemia Care for Dialysis-Dependent Patients
KDIGO-Medscape-ANNA CME Activity
This new CME educational activity, developed through a strategic collaboration between KDIGO, the American Nephrology Nurses Association (ANNA), and Medscape Education, explores current approaches to anemia care for patients with dialysis-dependent CKD.
Faculty Wolfgang Winkelmayer, MD (United States), Leah Foster Smith, MSN (United States), and Jennifer Branch, DNP (United States) provide expert perspectives and practical guidance for keeping current with evolving anemia management. CME/CNE/ABIM MOC/ICPE credit is available. Learn more.
| | |
New Frontiers in IgA Nephropathy: Understanding the Role of B-Cell Modulation
KDIGO-Medscape CME Activity
This new CME educational activity explores the evolving role of B-cell modulation in IgA nephropathy (IgAN). Faculty Jonathan Barratt, PhD (United Kingdom), and Kirk Campbell, MD (United States) review the role of the B-cell pathway in IgAN and key clinical evidence for B-cell–modulating therapies, with a focus on integrating emerging treatment approaches into clinical practice. CME/CNE/ICPE credit is available. Access the activity.
| | |
Transforming Care in C3G and IC-MPGN: Advancing Diagnosis, Disease Monitoring & Targeted Complement Therapy Across the Patient Journey
On-demand CME Program
This CME/CE program explores best practices for managing pediatric and adult patients with complement-mediated kidney diseases, including C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Through expert-led activities featuring Sayna Norouzi, MD (United States); Ankana Daga, MD (United States); and Richard Lafayette, MD (United States), the program addresses diagnosis and disease monitoring, evolving complement-targeted therapies, and practical considerations for incorporating new treatment options and shared decision-making into patient care. Learn more.
| | |
About KDIGO
KDIGO is a Belgian foundation committed to developing and implementing global nephrology guidelines that improve outcomes for people with kidney disease. KDIGO is independent, volunteer-led, self-managed, and accountable to the public and the people it serves. KDIGO thanks our annual supporters for their partnership. Learn more.
| | | | |
